MDWD — MediWound Ltd.
Is MDWD overbought or oversold? Here is the current MarketMoodz read.
MediWound Ltd. (MDWD) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $13.55. The rating moved from Strong Oversold to Oversold on November 16, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$13.55
- Last changeMoved from Strong Oversold to Oversold on November 16, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
MediWound Ltd. (MDWD) is a commercial-stage specialty wound care company with a differentiated enzymatic debridement offering that targets a focused hospital and specialty channel. The company benefits from a clear niche, potential for partnerships to accelerate geographic and channel expansion, and sector dynamics that favor specialty care and distributor flows. Near-term upside depends on continued commercial traction, expansion of payer coverage, and successful execution on partnerships or channel growth. Key challenges include adoption and reimbursement risk, the need for additional capital if revenue growth underperforms, clinical/regulatory uncertainty, and small-cap liquidity-driven volatility. Absent macro shocks, the stock is likely to track company-specific news flow and adoption metrics over the coming weeks.
Key factors
- Commercial-stage wound care franchise with differentiated enzymatic debridement technology addressing burns and other acute wounds
- Clear niche market positioning with limited direct competitors for rapid, non-surgical eschar removal, supporting pricing power in specific hospital settings
- Near-term commercial expansion and potential geographic or channel partnerships that could drive revenue scale and margin improvement
- Favorable readthroughs in specialty/distributor channels that support uptake in infusion/specialty pharmacy and hospital settings
- Measured market tone and limited volatility in the near-term macro window, which reduces downside driven by macro shocks and allows focus on company-specific catalysts
Risks
- Commercial adoption risk: slower-than-expected hospital uptake, limited prescription volumes, or weak payer reimbursement limiting revenue growth
- Regulatory and clinical risk: setbacks from additional clinical data, label restrictions, or post-market requirements could materially affect sales
- Balance-sheet / funding risk: as a smaller-cap therapeutic company, potential need for capital raises or dilutive financing if revenue growth lags
- Competition and alternative therapies: competing debridement techniques or new entrants could pressure pricing and share
- Policy and reimbursement pressure: regulatory/antitrust shifts or changes in Medicare/insurer coverage could reduce addressable market or pricing
- Volatility and liquidity risk typical of small-cap biotechs, which can amplify share-price moves around news or financing events
See today's live rating, score and targets
Members see the live hourly rating for MDWD — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.